TARS - Company ID 0001819790
The table below shows Tarsus Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $162.05M | $118.70M | $102.66M | $78.33M | $48.12M | $40.81M |
| Cost of revenue | $9.40M | - | - | $5.21M | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $22.35M | $16.28M | $15.59M | $14.41M | $12.13M | $12.32M |
Tarsus Pharmaceuticals, Inc. reported annual revenue of $451.36M for fiscal year 2025. That is up 146.7% from $182.95M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $136.43M |
| $108.63M |
| $103.01M |
| $85.00M |
| $57.91M |
| $58.79M |
| Operating income | -$6.12M | -$14.53M | -$22.18M | -$26.28M | -$25.16M | -$33.30M |
| Income tax | $2.35M | - | - | $0.00 | - | - |
| Net income | -$6.97M | -$12.59M | -$20.34M | -$25.12M | -$23.42M | -$33.29M |
| EPS (diluted) | -$0.16 | -$0.30 | -$0.48 | -$0.64 | -$0.61 | -$0.88 |